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In several recent conferences, the principal questions 
have been whether xenotransplantation technology 
should be encouraged and, if so, how it should be 
regulated. Because the prospect of successful trans-
plantation of animal organs into humans is still re-
mote, the rush to achieve consensus about clinical 
application 1,2 would be inexplicable were it not for 
two ostensibly unrelated issues. The first is the small 
but undeniable theoretical hazard of causing new hu-
man infections with the intermingling of tissues 
from different species. The second, advanced by 
animal-rights advocates, concerns the spiritual and 
ethical relationship of humans to animals. (J Am 
ColI Surg 1998;186:383-387. © 1998 by the 
American College of Surgeons) 
CLOSELY RELATED SPECIES 
The rhetoric of these discussions has been height-
ened by the fact that all clinical organ xenotransplan-
tations attempted since 1963 have failed, including 
>25 involving subhuman primate donors (19 re-
ported or unreported chimpanzees, 10 baboons, and 
1 [or 2] Rhesus monkeys). This experience began 
with Reemtsma and associates,3 who proved in 1963 
that kidneys from at least two subhuman primate 
donor species (Rhesus and chimpanzee) would not 
be rejected hyperacutely by humans. In fact, one of 
his chimpanzee xenografts functioned for 9 months. 
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However, Reemtsma was the first to recognize that 
the humanoid qualities and threatened extinction of 
the chimpanzee would prevent its widespread use as a 
donor. 
Later in 1963, a team at the University of 
Colorado/Minnesota showed that baboon kidneys 
also would escape hyperacute rejection. In contrast to 
the chimpanzee, baboons flourished, and still do, in 
southern and central Mrica. The six baboon renal 
xenografts of 1963 supported dialysis-free life for 
6-60 days before undergoing fierce cellular 
rejection.4 
In addition, all of the baboon kidneys had occlu-
sive endotheliolitis that was severe enough to cause 
regional parenchymal infarcts and islands of gan-
grene. We concluded by early 1964 that this humoral 
component of xenograft rejection could not be con-
trolled with cell-directed immune suppression (aza-
thioprine and prednisone at the time). A moratorium 
was self-imposed on further attempts. 
This hiatus lasted for 28 years, until investiga-
tions by Murase and colleagues5 with the hamster-to-
rat model appeared to justifY a further trial. In this 
strain combination, in which the immune barrier 
resembles that between the baboon and human,6 the 
combination ofT-ceIl-specific immune suppression 
with tacrolimus plus B-cell-directed cyclophospha-
mide permitted the unprecedented routine survival 
of heart and liver xenografts for > 100 days. 
In June 1992 and January 1993, two baboon-to-
human orthotopic liver transplantations were per-
formed in patients with chronic end-stage organ fail-
ure caused by hepatitis B virus infection. Two factors 
in addition to proximity to death influenced their 
candidacy. First, it was thought (and subsequently 
confirmed) that baboon hepatocytes were not subject 
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sumably because they do not have appropriate viral 
receptors. Second, there were medical contraindica-
tions to conventional allotransplant candidacy (eg, 
human immunodeficiency virus, older age, cardiac 
disease). Although it was anticipated that the 
xenografts would provide definitive, as opposed to 
bridge, function, both grafts failed after 70 and 26 
days despite heavy immunosuppression with ta-
crolimus, cyclophosphamide, prostaglandin E1' 
and prednisone.8,9 
The liver xenografts showed no trace of the oc-
clusive endotheliolitis that had been responsible for 
patchy gangrene of the 1963 kidney xenografts and 
in the baboon-heart xenograft of Leonard Bailey's 
Baby Fae case. 10 Cellular rejection was found in only 
1 of the 14 biopsies or autopsy specimens from the 
two xenografts (n = 7 each). The only positive bi-
opsy specimen, on day 12 in the first case, showed 
only mild cellular rejection. 
Although the two livers were not rejected hyper-
acutely or by the usual delayed mechanisms of allo-
grafts, red blood cell sludging and a few polymorpho-
nuclear leukocytes were seen in the sinusoids of the 
xenograft biopsy specimens 1 hour after revascular-
ization. Upon close examination, a very fine mi-
crosteatosis was seen in the hepatocytes of both xeno-
grafts, which dramatically worsened over the next 
few days, especially in the second case.8,9 
The grafts had survived an aborted hyperacute 
rejection. Although IgM found in the I-hour biopsy 
specimen had largely cleared at 12 days, significant 
amounts ofIgG remained in the xenografts through-
out the survival periods of both patients. Total com-
plement remained depleted for the first 2 weeks after 
transplantation, while complement components C3, 
C4, and C5 became undetectable. Circulating im-
mune complexes appeared early, receded, and reap-
peared sporadically until the time of death. 8,9 
Good control of adaptive immunity had un-
masked a low-grade innate immune response which, 
we concluded, could not be treated safely, if at all, 
with any combination of agents currently available. 
Consequently, we canceled the last two patients in 
our series of four approved by the Institutional Re-
view Board. One of the unanswered questions was 
whether the species restriction of complement de-
scribed in 1994 by Valdivia and coauthors9, 11 played 
a role in the failures. Because the liver is the principal 
or sole source of most complement components, the 
complement was eventually transformed to poten-
tially protective baboon phenotype in both cases,9 
] Am Col{ Surg 
Table 1. Effectors Involved in Response to Cytopathic 
Parasites and Discordant ue~gr_a_ft_s_* __ 
The tirst line of defense 
Interferons 
Macrophages 
'I/o T cells 
Natural killer cells 
B cells 





* Reviewed in references 13-15. 
but because this change required several days, it may 
have been too late to be advantageous. 
DISTANTLY RELATED SPECIES 
In the pessimistic climate that followed the liver xe-
no transplant failures, it seemed inconceivable that 
the use of even more discordant donors could ever be 
seriously entertained. This period of pessimism, 
however, preceded insight into the xenogeneic bar-
rier that has brought transplantation immunity onto 
common ground with infectious immunity, with 
particular reference to graft acceptance and acquired 
tolerance. 12 
Cytopathic parasites 
From the perspective of infection, the immune 
system makes an immediate strategic decision, based 
on differentiation of cytopathic parasites from the 
less dangerous noncytopathic parasites (ie, viruses, 
bacteria, or protozoans). The antigenic signal of 
"danger" issued by a cytopathic invader may come 
from its rigid, densely arranged, and ordered repeti-
tive epitopes, aided by lipopolysaccharides and other 
unknown means. 13-] 5 
The host immune armamentarium is mobilized 
to eliminate the pathogens quickly and completely, 
with little regard for damage to infected host cells. 
The first line of defense is dominated by interfc~ronsI 
macro phages, "118 T cells, natural killer cells, and by 
B cells, which recognize suspect antigen patterns and 
may be activated without Tcell help. In addition, 
nonspecific or less specific effector mechanisms such 
as complement, interleukins, and phagocytes are 
promptly involved13- 15 (Table O. 
The transplant analogy 
These are the same mechanisms, predominantly 
those of innate immunity, that are responsible f;)r the 
hyperacute rejection of discordant xenografts and 




Transfected COS' Cell 
• African green monkey 
fibroblast 
Lysed by human serum 
Figure 1. COS cells are lysed by human serum after their transfec-
tion with the Gal-a (1,3) Gal gene (see text). COS, cultured Mri-
can green monkey fibroblasts. 
also of allografts transplanted to ABO-incompatible 
or highly sensitized recipients.9 The best-character-
ized signal on the cells of discordant xenografts is the 
terminal residue Gal-a (1,3) Gal,l6,17 This antigen is 
chemically similar to ABO antigens and is found on 
numerous bacteria, protozoa, and viruses. IS 
In an effort to prevent clinical hyperacute xeno-
graft rejection, investigators have transfected human 
complement regulatory proteins into pigsy>-21 This 
results only in temporary delay of xenograft destruc-
tion.22,23 The reason is that the other mechanisms of 
innate immunity (shown in Table 1) promptly cause 
inexorable rejection. To avoid the devastating conse-
quences of these effectors, additional genetic manip-
ulation will be required, whereby antigens are elimi-
nated or equivalent human genes are introduced. 
Gene knockout procedures have not yet been 
done in the pig. Using molecular technologies, 
though, some of which already have been shown to 
be applicable in pigs, the team of Osman and co-
workers24 in Australia has been able to reduce cell-
surface expression of the Gal-a-Gal gene product in 
cultured Mrican green monkey fibroblasts (so-called 
COS cells) to negligible levels. The experiments were 
staged. As a first step, the COS cells, which normally 
do not express the Gal-a-Gal epitope, were trans-
fected with the Gal eDNA. Because these transfected 
COS cells now presented a Gal-a-Gal target, they 
were vigorously lysed by the antibodies in human 
serum (Fig. 1). 
The anti-Gal lysis was reduced, but not elimi-
nated, by transfection of the altered COS cell with 
human a-galactosidase, which cleaves off a-linked 
galactosyl residues of the target epitope (Fig. 2). Be-
cause this exposes subterminal saccharides (ie, 
N-acetyllactosamine), to which there also are "natu-
ral" human antibodies, lysis is only reduced. The ad-
ditional insertion of an a(1,2)fucosyltransferase 
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• 
Added transfection 
of a-galactosidase ~ 
• 
Reduced lysis 
by human serum 
Figure 2. Insertion of the a-galactosidase gene diminishes, but does 
not eliminate, the lysis shown in Figure 1 (see text). 
gene, however, resulted in the substitution of Gal-a 
Gal with the nonimmunogenic H substance (ie, the 
universally tolerated 0 blood-group antigen). The 
double transfection (galactosidase plus fucosyltrans-
ferase) completely eliminated complement-mediated 
lysis of the COS cells (Fig. 3). 
The a-galactosidase gene has not yet been trans-
fected in pigs, but this has been accomplished with 
the a-fucosyltransferase gene by John Logan and as-
sociates of the Nextran Corporation in collaboration 
with Sharma and associates at Duke University.25 
Stable double transfection in pigs would seem to be 
only a matter of time. 
WHAT LIES BEYOND? 
There has been much speculation about what unan-
ticipated obstacles will arise when, and if, the first 
barrier of hyperacute rejection is broken down.26,27 
With an understanding of the commonality of infec-
tious and transplantation immunity, 12 the answer al-
ready is obvious, and not alarming. In contrast to the 
cytopathic parasites, whose antigens are mimicked by 
discordant xenografts, the noncytopathic microor-
ganisms are routinely accommodated by the host in 
Added a-galactosidase I!!!l 
and 
Fucosyltransferase lSI 
No lysis by 
human serum 
Figure 3. Additional insertion of the a(I ,2)fucosyltransferase gene 
converts the xenogeneic Gal-a (1,3) Gal antigen to the H (0, or 
universal donor) antigen and eliminates lysis (see text). 
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Figure 4. (A) Similar selective migration to lymphoid organs by 
invasive non cytopathic microorganisms and passenger leukocytes 
from organ grafts. (B) Ubiquitous antigen spread after a pause at 
the locations shown in A. 
ways made possible by the major histocompatibil.ity 
complex restriction, which allows both host and lll-
vader to survive. 13-15,28 For this fundamental discov-
ery,29,30 Doherty and Zinkernagel were awarded the 
1996 Nobel Prize. In the noncytopathic scenario, the 
highest priority is not elimination of the pathogens, 
but avoidance of damage to host tissues. 
The recognition and effector mechanisms that 
evolved to deal with noncytopathic infections are the 
same as those that have been subverted successfully 
for organ allotransplantation with the aid ?f im~u­
nosuppression. 12 In both transplant and lllfectJous 
circumstances, the immune response is governed by 
the antigen's migration and localizatio~K The traffi~ is 
oriented selectively at first to lymphOId organs (FIg. 
4A), where activation-associated clonal exhaustion/ 
deletion occurs. 12 Ultimately, the antigen escapes to 
ubiquitous nonlymphoid areas (Fig. 4B), where a 
secondary tolerance mechanism of immune indiffer-
ence may contribute in the transplant settin~ to 
maintenance of the chimerism-dependent deletIOn/ 
exhaustion that takes place in organized lymphoid 
collections. No other mechanisms of tolerance, in-
cluding negative regulation, are essential to explain 
graft acceptance. 12 . 
The rules for transgenic xenografts, whose antI-
genic epitopes are altered enough to avoid evoking 
innate immunity, should be the same as those that 
permit the characteristic immunologic confronta-
tion and resolution first identified in kidney allograft 
recipients receiving azathioprine and dose-
J Am Coil Surg 
maneuverable prednisone.31 It has been possible 
since then to exploit this discovery with progres:;ively 
greater efficiency using increasingly potent baseline 
immunosuppressants, but the essential pattern has 
remained the same. The only difference in principle 
from response to a noncytopathic infection is that a 
double immune reaction is involved after transplan-
tation, in which responses of coexisting donor and 
recipient immune cells, each to the other, cause re-
ciprocal clonal expansion, followed by variable clonal 
exhaustion and deletion, which are maintained by 
persistent microchimerism. 12,32-34 
CONCLUSIONS 
Far from being bleak, the future of xenotransplanta-
tion is brighter than at any previous time because 
what must be done to succeed has become remark-
ably clear. Although nature did not evolve defensi:-e 
barriers to frustrate transplant surgeons, rules laId 
down by coevolution of the host-parasite relation-
ship must be followed. First, we have already learned 
empirically with allotransplantation how to work 
around, or, more accurately, work with, the defense 
mechanisms developed by nature to control noncy-
topathic infections. 
Second, because this approach will not work for 
the xenogeneic antigens that resemble cytopathic m.i-
croorganisms, these antigens in animal donors WIll 
have to be deleted or changed. It remains to be seen 
h h . .. fit 9,11.26,27 w et er speCIes restnctIOn 0 comp emen 
will necessitate transfection of complement regula-
tory proteins to prevent continuous complem~nt ac-
tivation. If so, strategies for xenotransplantanon of 
the liver will be more complex because this organ is 
the source of most complement. 
Finally, bridge trials with xenografts to provide 
desperately needed temporary organ function for 
candidates waiting for allografts may be the best way, 
consistent with ethical patient care, to obtain infor-
mation about the efficacy of donor species alteration. 
If it is emphasized that these efforts are being made 
with patient benefit foremost in mind, the public will 
support such trials. If we do not, or ~f we i.ndulge in 
exaggerated claims, xenotransplantatJon WIll be shut 
down. 
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